Pure Global
NCT06249308

Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC )

A Multi-center, Perspective, Observational Case-control Study to Develop and Validate an Ovarian Cancer Early Detection Model Based on Peripheral Blood Multi-omic Analysis and Machine Learning
Fudan University·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Ovarian Cancer
Drug/Device/Intervention
Blood collection
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Fudan University
Location
Guangzhou,Shenyang,Shanghai, China
Timeline & enrollment
Phase
N/A
Start date
Dec 18, 2023
End date
Dec 31, 2026
Enrollment
168 participants
Primary outcome

The performance of cfDNA methylation-based model for discriminating ovarian cancer versus non-cancer.

Summary

This study is a multi-center, observational study aiming at developing a machine
 learning-based early detection model using prospectively collected liquid biopsy samples from
 newly diagnosed ovarian cancer.

ICD-10 classifications
Malignant neoplasm of ovarySecondary malignant neoplasm of ovaryBenign neoplasm of ovaryOvarian pregnancyOvarian dysfunction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06249308
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06249308 through Pure Global AI's free database. This phase not specified trial is sponsored by Fudan University and is currently Recruiting. The study focuses on Ovarian Cancer. Target enrollment is 168 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.